Clinical Trials · NCT01442246

Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.

Name: Evaluation of Adjuvant Hormonal Treatment for 24 Months After Radical Prostatectomy in High Risk of Recurrence Patients.
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

Active Not RecruitingPhase 3Gonadorelin

Phase: Phase 3
Recruitment status: Active Not Recruiting
Sponsor: UNICANCER
Enrollment: 700
Start date: Jul 2011
Locations: 35 sites, France
Primary endpoint: The principal criterion is the evaluation of effectiveness in terms of survival without metastases to 10 years, of adjuvant treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy.

View Gonadorelin compound reference